entinostat has been researched along with Peritoneal Carcinomatosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, VG | 1 |
| Hirst, J | 1 |
| Petersen, S | 1 |
| Roby, KF | 1 |
| Kusch, M | 1 |
| Zhou, H | 1 |
| Clive, ML | 1 |
| Jewell, A | 1 |
| Pathak, HB | 1 |
| Godwin, AK | 1 |
| Wilson, AJ | 1 |
| Crispens, MA | 1 |
| Cybulla, E | 1 |
| Vindigni, A | 1 |
| Fuh, KC | 1 |
| Khabele, D | 1 |
1 other study available for entinostat and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; Carcinoma, Ovari | 2021 |